Alpha Tau sets Nov. 16 call to review interim glioblastoma trial results

DRTS•2026-11-12

Alpha Tau will review new interim results from its U.S. multicenter REGAIN trial on Nov. 16, 2026, at 8:30 a.m. ET. The trial evaluates Alpha DaRT radiation therapy in patients with recurrent glioblastoma.

1. Trial results call

Alpha Tau will review new interim REGAIN trial results on Nov. 16, 2026, at 8:30 a.m. ET. The U.S. multicenter trial evaluates Alpha DaRT radiation therapy in patients with recurrent glioblastoma. Results will be presented at the Society for Neuro-Oncology meeting, scheduled for Nov. 12-15, 2026, in Philadelphia.

Sources

Alpha Tau sets Nov. 16 call to review interim glioblastoma trial results

Sec

Alpha Tau sets Nov. 16 call to review interim glioblastoma trial results

1. Trial results call

Related News

Powerfleet plans to attend Craig-Hallum and Roth investor conferences

SOLV Energy 3Q26 net income jumps 75% year over year to $122.75 million

Trio-Tech Q1 FY27 net income rises to $846,000; revenue increases 29% to $19.95 million

Sources

Alpha Tau sets Nov. 16 call to review interim glioblastoma trial results

Only 33% of enterprises meet AI business case, Rackspace-HFS study finds

Agassi Sports Entertainment partners with Sinclair, Tennis Channel on media advertising